These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21035976)

  • 1. Determination of L-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC-ED.
    Bugamelli F; Marcheselli C; Barba E; Raggi MA
    J Pharm Biomed Anal; 2011 Feb; 54(3):562-7. PubMed ID: 21035976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous determination of levodopa, carbidopa, entacapone, tolcapone, 3-O-methyldopa and dopamine in human plasma by an HPLC-MS/MS method.
    Ribeiro RP; Gasparetto JC; de Oliveira Vilhena R; Guimarães de Francisco TM; Martins CA; Cardoso MA; Pontarolo R; de Carvalho KA
    Bioanalysis; 2015; 7(2):207-20. PubMed ID: 25587837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new HILIC-MS/MS method for the simultaneous analysis of carbidopa, levodopa, and its metabolites in human plasma.
    Vilhena Rde O; Pontes FL; Marson BM; Ribeiro RP; de Carvalho KA; Cardoso MA; Pontarolo R
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Sep; 967():41-9. PubMed ID: 25063927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers.
    Nyholm D; Ehrnebo M; Lewander T; Trolin CG; Bäckström T; Panagiotidis G; Spira J; Nyström C; Aquilonius SM
    Acta Neurol Scand; 2013 Feb; 127(2):124-32. PubMed ID: 22762460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC-ESI-MS/MS: application for a pharmacokinetic study with a levodopa/benserazide formulation.
    César Ida C; Byrro RM; Cardoso FF; Mundim IM; Teixeira Lde S; da Silva EP; Gomes SA; Bonfim RR; Pianetti GA
    J Pharm Biomed Anal; 2011 Dec; 56(5):1094-100. PubMed ID: 21856105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micellar HPLC-UV method for the simultaneous determination of levodopa, carbidopa and entacapone in pharmaceuticals and human plasma.
    Belal F; Ibrahim F; Sheribah ZA; Alaa H
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Aug; 1091():36-45. PubMed ID: 29843067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.
    Paija O; Laine K; Kultalahti ER; Leinonen M; Huupponen R; Gordin A; Reinikainen K
    Clin Neuropharmacol; 2005; 28(3):115-9. PubMed ID: 15965309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies.
    LeWitt PA; Jennings D; Lyons KE; Pahwa R; Rabinowicz AL; Wang J; Guarnieri M; Hubble JP; Murck H
    Mov Disord; 2009 Jul; 24(9):1319-24. PubMed ID: 19412946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a high-performance liquid chromatography-electrospray ionization-MS/MS method for the simultaneous quantitation of levodopa and carbidopa in human plasma.
    César IC; Byrro RM; Santana E Silva Cardoso FF; Mundim IM; Souza Teixeira L; Gomes SA; Bonfim RR; Pianetti GA
    J Mass Spectrom; 2011 Sep; 46(9):943-8. PubMed ID: 21915959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
    Heikkinen H; Varhe A; Laine T; Puttonen J; Kela M; Kaakkola S; Reinikainen K
    Br J Clin Pharmacol; 2002 Oct; 54(4):363-71. PubMed ID: 12392583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug.
    Brusa L; Bassi A; Lunardi G; Fedele E; Peppe A; Stefani A; Pasqualetti P; Stanzione P; Pierantozzi M
    Eur J Neurol; 2004 Sep; 11(9):593-606. PubMed ID: 15379738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
    Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A;
    Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study.
    Deleu D; Sarre S; Ebinger G; Michotte Y
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1323-31. PubMed ID: 7791104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients.
    Müller T; Muhlack S
    J Neural Transm (Vienna); 2014 Jun; 121(6):643-8. PubMed ID: 24390153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-performance liquid chromatography method for the quantification of entacapone in human plasma.
    Ramakrishna NV; Vishwottam KN; Wishu S; Koteshwara M; Chidambara J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Sep; 823(2):189-94. PubMed ID: 16009606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
    Müller T; Schlegel E; Zingler S; Thiede HM
    Cells; 2022 Apr; 11(9):. PubMed ID: 35563817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
    Müller T; Kolf K; Ander L; Woitalla D; Muhlack S
    Clin Neuropharmacol; 2008; 31(3):134-40. PubMed ID: 18520980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
    Müller T; Ander L; Kolf K; Woitalla D; Muhlack S
    J Neural Transm (Vienna); 2007; 114(11):1457-62. PubMed ID: 17564755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
    Rouru J; Gordin A; Huupponen R; Huhtala S; Savontaus E; Korpela K; Reinikainen K; Scheinin M
    Eur J Clin Pharmacol; 1999 Aug; 55(6):461-7. PubMed ID: 10492060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.